10-K: Alzamend Neuro, Inc. Files 10-K Report Detailing Financials and Clinical Progress

Alzamend Neuro, Inc. has released its annual 10-K report, outlining its financial status, clinical trial progress, and future strategies for developing treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD.

Summary

• Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, is focused on developing treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD.
• The company's pipeline includes AL001, an ionic cocrystal of lithium, and ALZN002, a cell-based therapeutic vaccine.
• AL001 has completed a Phase I clinical trial and a Phase IIA multiple ascending dose trial, identifying a maximum tolerated dose of 240 mg three times daily.
• Investigational New Drug applications for AL001 have been submitted and approved by the FDA for bipolar disorder, major depressive disorder, and PTSD.
• ALZN002 has initiated a Phase I/IIA clinical trial to treat mild to moderate dementia of the Alzheimers type.
• The company reported a net loss of $9.9 million for the fiscal year ended April 30, 2024, compared to a net loss of $14.9 million for the previous year.
• As of April 30, 2024, the company had $376,000 in cash and cash equivalents.
• The company has a going concern warning from its independent auditor due to insufficient capital to fund operations.
• The company is pursuing additional funding through equity sales and strategic transactions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and some positive preclinical data, the company's financial situation is precarious, with a going concern warning and a material weakness in internal controls. The need for substantial additional funding and the risk of delisting from Nasdaq also weigh heavily on the sentiment.

Positives

• AL001 has shown positive results in preclinical studies, preventing cognitive deficits, depression, and irritability in mice models.
• AL001 is positioned for a Section 505(b)(2) regulatory pathway, potentially expediting approval.
• The company believes AL001 and ALZN002 are positioned for breakthrough therapy designations due to their positive effects on beta-amyloids.
• The company has successfully identified a maximum tolerated dose for AL001, which is designed to be unlikely to require therapeutic drug monitoring.
• The company has received study may proceed letters from the FDA for AL001 for bipolar disorder, major depressive disorder, and PTSD.

Negatives

• The company has a limited operating history and has not generated any revenue.
• The company has a going concern warning from its independent auditor due to insufficient capital to fund operations.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is substantially dependent on the success of its product candidates, which may not receive regulatory approval or be successfully commercialized.
• The company is subject to various risks related to its intellectual property rights, affiliates, and related party transactions.

Risks

• The company needs to obtain substantial additional funding to complete the development and commercialization of AL001 and ALZN002.
• The company is at an early stage of clinical development and currently has no source of near-term revenue.
• The company has a limited operating history on which to judge its business prospects and management.
• The company has both operational and financial milestones that must be met to maintain the licensing rights to its current technology and intellectual property.
• The company is substantially dependent on the success of its product candidates, which may not receive regulatory approval or be successfully commercialized.
• The company has identified a material weakness in its internal control over financial reporting.
• The company may not be able to regain compliance with Nasdaq listing requirements, which could result in delisting.

Future Outlook

The company intends to develop and commercialize therapeutics that are better than existing treatments and have the potential to significantly improve the lives of individuals afflicted by Alzheimers, BD, MDD and PTSD. The company plans to initiate clinical trials at the maximum tolerated dose to determine relative increased lithium levels in the brain compared to a marketed lithium salt for BD, MDD and PTSD. The company also plans to initiate two safety and efficacy clinical trials in subjects with mild to moderate dementia of the Alzheimers type.

Management Comments

• The company aims to bring treatments or potential cures to market as quickly as possible.
• The company intends to commercialize AL001 and ALZN002 by seeking FDA marketing approval and partnering with biopharmaceutical companies.

Industry Context

The company operates in a highly competitive biopharmaceutical industry, facing competition from both large and small pharmaceutical and biotechnology companies, as well as academic and research institutions. The market for treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD is significant, with large financial support available from numerous national and international pharmaceutical companies and various governments and worldwide agencies.

Comparison to Industry Standards

• The company's approach to re-engineer lithium in solid dosage forms to optimize performance is a novel approach compared to traditional lithium treatments.
• The company's cell-based therapeutic vaccine approach for ALZN002 is a unique approach compared to passive immunization treatments.
• The company's focus on translational and functional endpoints to efficiently develop product candidates is a common strategy in the biopharmaceutical industry.
• The company's strategy to partner with biopharmaceutical companies for commercialization is a common practice in the industry.
• The company's financial results are typical for a clinical-stage biopharmaceutical company with no approved products.

Related Party Transactions

• The company has entered into a securities purchase agreement with Ault Lending, a related party, for the purchase of Series B Convertible Preferred Stock and warrants.
• The company has a marketing and brand development agreement with AULT, a related party.
• The company has a settlement agreement with ALSF, a related party, for the return of shares and warrants in settlement of a note receivable.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding and the risk of delisting from Nasdaq.
• Employees may be affected by the company's financial instability and potential restructuring.
• Patients and caregivers may benefit from the company's development of new treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD.
• Suppliers and creditors may be affected by the company's financial instability and potential inability to meet its obligations.

Next Steps

• The company intends to initiate clinical trials at the maximum tolerated dose to determine relative increased lithium levels in the brain compared to a marketed lithium salt for BD, MDD and PTSD.
• The company plans to initiate two safety and efficacy clinical trials in subjects with mild to moderate dementia of the Alzheimers type.
• The company is pursuing the engagement of a replacement CRO for the ALZN002 clinical trial.

Key Dates

Keywords

Alzamend Neuro, AL001, ALZN002, Alzheimers, Bipolar Disorder, Major Depressive Disorder, PTSD, Lithium, Clinical Trials, Biopharmaceutical, Neurodegenerative Diseases, Psychiatric Disorders, Immunotherapy, FDA, Drug Development